MGF: Molecular Structure

Molecular Structure Overview#

MGF (Mechano Growth Factor) is a 24-amino acid linear peptide with a molecular formula of C121H200N42O39 and a molecular weight of 2867.15 Daltons. The CAS number is 80214-83-1. The peptide corresponds to the unique C-terminal E-domain of the human IGF-1Ec splice variant, a region not shared with other IGF-1 isoforms.

The MGF E-domain peptide is generated through alternative splicing of the IGF-1 gene. In humans, a 49-base pair insert from exon 5 of the IGF-1 gene causes a reading frame shift in the IGF-1Ec transcript, producing a completely different carboxy-terminal peptide sequence compared to the predominant IGF-1Ea isoform. This frame-shifted E-domain is the MGF peptide.

Amino Acid Sequence Analysis#

The complete amino acid sequence of MGF in single-letter code is:

YQPPSTNKNTKSQRRKGSTFEEHK

In three-letter code:

H-Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-His-Lys-OH

Sequence Characteristics#

The MGF peptide has several notable structural features:

• High basicity: The sequence contains four lysine (Lys) residues and two arginine (Arg) residues, giving the peptide a strong net positive charge at physiological pH. This cationic character may be important for membrane interactions and cell signaling
• Proline-rich N-terminus: Positions 3 and 4 are both proline residues (Pro-Pro), which introduce a rigid kink in the peptide backbone. This structural motif may be important for the peptide's biological activity and receptor recognition
• No cysteine residues: The absence of cysteine means MGF cannot form disulfide bonds, contributing to its linear, flexible structure
• Aromatic residues: Tyrosine (position 1), phenylalanine (position 20), and histidine (position 23) provide potential sites for receptor interactions through pi-stacking and hydrogen bonding

Comparison with Rodent MGF#

The rodent equivalent of human MGF arises from the IGF-1Eb splice variant, which contains a 52-base pair insert (compared to 49 bp in humans). The rodent MGF E-domain is 25 amino acids long versus 24 in humans, with several amino acid substitutions. The sequence YQPPSTNKNTKSQRRKGSTFEERK (with Arg instead of His at position 23) is commonly used in rodent studies.

Gene Structure and Splicing#

IGF-1 Gene Organization#

The human IGF-1 gene contains 6 exons. All IGF-1 mRNA transcripts include exons 3 and 4, which encode the mature 70-amino acid IGF-1 peptide (B, C, A, and D domains). The E-domain peptides arise from alternative splicing of exons 5 and 6:

The 49-bp insert from exon 5 in the IGF-1Ec transcript introduces a reading frame shift that produces the unique MGF E-domain sequence. This frame shift means that while the mature IGF-1 peptide encoded by exons 3 and 4 is identical across all three splice variants, the C-terminal E-domain peptide sequences are completely different.

Splicing Regulation#

The alternative splicing that produces MGF is regulated by mechanical stress and tissue damage. Following muscle injury or exercise, the IGF-1Ec splice variant is upregulated within hours, before the IGF-1Ea variant. This temporal pattern is controlled by splicing factors that respond to mechanotransduction signaling pathways. The specific splicing factors involved remain incompletely characterized, though they likely include members of the SR protein family and other RNA-binding proteins.

Structural Biology#

Three-Dimensional Structure#

The MGF E-domain peptide has not been crystallized in isolation, and no X-ray crystallographic or NMR structure has been reported. Based on computational modeling and circular dichroism studies, the peptide is predicted to adopt a largely disordered conformation in solution, with the Pro-Pro motif at positions 3-4 introducing a rigid turn. The C-terminal region (approximately residues 16-24) may form a transient alpha-helical structure, particularly upon interaction with binding partners.

The lack of stable secondary structure is consistent with MGF functioning as an intrinsically disordered peptide (IDP), a class of proteins that adopt defined conformations only upon binding to their targets. This structural flexibility may allow MGF to interact with multiple signaling partners.

Receptor Binding#

The MGF E-domain peptide does not bind to the IGF-1 receptor (IGF-1R) or the insulin receptor. Its biological activity is mediated through a distinct, as-yet-unidentified receptor or signaling pathway. This is a critical distinction from mature IGF-1, which acts primarily through the IGF-1R.

Evidence suggests that MGF may signal through interactions with the extracellular matrix, membrane-associated proteoglycans, or an uncharacterized cell-surface receptor. The precise molecular mechanism by which MGF activates satellite cells and promotes proliferation remains one of the major unresolved questions in MGF biology.

Pharmacokinetic Properties#

Absorption and Distribution#

Following subcutaneous injection, MGF is rapidly absorbed into the local tissue and circulation. However, the peptide is extremely susceptible to proteolytic degradation, with an estimated half-life of approximately 5-7 minutes in serum. This extremely short half-life severely limits the practical utility of unmodified MGF as a therapeutic agent.

Metabolism and Elimination#

MGF is rapidly degraded by serum proteases, particularly aminopeptidases and endopeptidases. The multiple basic residues (Lys, Arg) provide numerous cleavage sites for trypsin-like proteases. The rapid degradation means that only a small fraction of an administered dose reaches target tissues in biologically active form.

PEGylation Strategy#

The extremely short half-life of native MGF has led to the development of PEG-MGF (pegylated MGF), in which a polyethylene glycol (PEG) moiety is covalently attached to the peptide. PEGylation extends the circulating half-life from minutes to hours by sterically shielding the peptide from proteolytic attack and reducing renal clearance. PEG-MGF is a distinct research compound with different pharmacokinetic and potentially different pharmacodynamic properties compared to native MGF.

Physical and Chemical Properties#

Analytical Methods#

MGF is characterized and quantified using standard peptide analytical methods including reverse-phase HPLC for purity assessment, LC-MS/MS for identification and quantification, and mass spectrometry for molecular weight confirmation. The unique amino acid sequence provides a distinctive fragmentation pattern in tandem mass spectrometry, enabling selective detection even in complex biological matrices.

Research into anti-doping detection methods for MGF has been published, including a 2015 study that characterized a biotechnologically produced full-length MGF using mass spectrometry specifically for doping control purposes. This work established reference standards and detection methodologies for identifying MGF misuse in sports.

Key Structural Differences from Related Peptides#

Related Reading#

• MGF overview and research guide
• Peptides similar to MGF
• MGF research evidence